Analysts Expect Merck & Company, Inc. (MRK) Will Post Quarterly Sales of $10.44 Billion
Brokerages expect Merck & Company, Inc. (NYSE:MRK) to announce sales of $10.44 billion for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Merck &’s earnings. The highest sales estimate is $10.52 billion and the lowest is $10.32 billion. Merck & reported sales of $10.54 billion during the same quarter last year, which indicates a negative year over year growth rate of 0.9%. The business is expected to issue its next quarterly earnings results before the market opens on Friday, October 27th.
On average, analysts expect that Merck & will report full year sales of $10.44 billion for the current year, with estimates ranging from $40.12 billion to $40.48 billion. For the next year, analysts anticipate that the firm will report sales of $41.25 billion per share, with estimates ranging from $40.60 billion to $41.87 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Merck &.
Merck & (NYSE:MRK) last released its earnings results on Friday, July 28th. The company reported $1.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.14. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The business had revenue of $9.93 billion for the quarter, compared to the consensus estimate of $9.75 billion. During the same period in the previous year, the company posted $0.93 earnings per share. The company’s revenue for the quarter was up .9% compared to the same quarter last year.
Several equities research analysts have recently weighed in on the stock. BMO Capital Markets reiterated an “outperform” rating and set a $72.00 target price on shares of Merck & in a research note on Thursday. Zacks Investment Research downgraded shares of Merck & from a “hold” rating to a “sell” rating in a research note on Wednesday. Credit Suisse Group reiterated an “outperform” rating and set a $74.00 target price (down previously from $75.00) on shares of Merck & in a research note on Tuesday, September 5th. Cowen and Company reiterated a “hold” rating and set a $70.00 target price on shares of Merck & in a research note on Friday, September 1st. Finally, Jefferies Group LLC reiterated a “sell” rating and set a $52.00 target price on shares of Merck & in a research note on Sunday, August 20th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $70.13.
Shares of Merck & (NYSE:MRK) opened at 63.83 on Friday. The company has a market capitalization of $174.09 billion, a P/E ratio of 34.56 and a beta of 0.80. The firm has a 50-day moving average price of $64.51 and a 200 day moving average price of $63.70. Merck & has a 12-month low of $58.29 and a 12-month high of $66.80.
The company also recently declared a quarterly dividend, which was paid on Friday, October 6th. Investors of record on Friday, September 15th were issued a dividend of $0.47 per share. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.95%. Merck &’s dividend payout ratio is currently 76.11%.
A number of institutional investors have recently modified their holdings of MRK. Vanguard Group Inc. increased its holdings in Merck & by 1.7% in the second quarter. Vanguard Group Inc. now owns 194,144,317 shares of the company’s stock valued at $12,442,709,000 after buying an additional 3,312,459 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Merck & by 71.5% in the second quarter. Arrowstreet Capital Limited Partnership now owns 6,281,855 shares of the company’s stock valued at $402,604,000 after buying an additional 2,618,435 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Merck & by 40.4% in the second quarter. Principal Financial Group Inc. now owns 8,012,726 shares of the company’s stock valued at $513,535,000 after buying an additional 2,304,142 shares in the last quarter. Canada Pension Plan Investment Board increased its holdings in Merck & by 70.4% in the first quarter. Canada Pension Plan Investment Board now owns 5,568,791 shares of the company’s stock valued at $353,841,000 after buying an additional 2,300,200 shares in the last quarter. Finally, Parametric Portfolio Associates LLC increased its holdings in Merck & by 36.3% in the second quarter. Parametric Portfolio Associates LLC now owns 7,766,906 shares of the company’s stock valued at $497,774,000 after buying an additional 2,070,487 shares in the last quarter. 72.91% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Analysts Expect Merck & Company, Inc. (MRK) Will Post Quarterly Sales of $10.44 Billion” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/10/13/analysts-expect-merck-company-inc-mrk-will-post-quarterly-sales-of-10-44-billion.html.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.